

4D Pharma Says MRx0518 Part B Study Enrolment Continues To Progress


4D Pharma Joins Landmark Study For Parkinson's Treatment Development


4D Pharma Files US Registration Statement For ADR Programme


IN BRIEF: 4d Pharma Reports Positive Data From Ongoing MRx051 Trials


IN BRIEF: 4D Pharma Proposes Merger With Longevity Acquisition


UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans


4D Pharma Reports Positive Results From Bowel Syndrome Treatment Trial


IN BRIEF: 4D Pharma Interim Loss Widens On R&D Costs Increase